



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 18 2000

Applicant: GRUENBERG, M.

Serial No.: 09/127,141

Filed: July 31, 1998

For: AUTOLOGOUS IMMUNE CELL
THERAPY: CELL COMPOSITIONS,
METHODS AND APPLICATIONS TO
TREATMENT OF HUMAN DISEASE

Art Unit: 1644

Examiner: Schwadran, R.

I hereby certify that this paper and the
attached papers are deposited with
the United States Postal Service at
class mail in an envelope addressed to:
Assistant Commissioner for Patents
Washington, D.C. 20231, on this date.

12/06/00

Date

Rita H. Jennings
Rita H. Jennings

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Form PTO-1449 (1 page) and cited reference for filing in connection with the above-identified application. Because this Supplemental Information Disclosure Statement is filed **after receipt of a First Office Action on the merits for the above-captioned application** but before either a Final Office Action or Notice of Allowance in the above-referenced application, a fee for filing this statement is included herewith. However, should said fee be either missing or incorrect, the Commissioner is authorized to charge deposit account No. 50-1213, for the appropriate fee as stated below:

- (X) The Commissioner is hereby authorized to charge the fee for the Information Disclosure Statement and any other fees that may be due under 37 C.F.R. §§ 1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman
Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24731-500F
Address all correspondence to:
Stephanie L. Seidman, Esq.
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4250 Executive Square,
La Jolla, California 92037
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL sseidman@hewm.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GRUENBERG, M.

Serial No.: 09/127,141

Filed: July 31, 1998

For: *AUTOLOGOUS IMMUNE CELL
THERAPY: CELL COMPOSITIONS,
METHODS AND APPLICATIONS TO
TREATMENT OF HUMAN DISEASE*

Art Unit: 1644

Examiner: Schwadran, R.



I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231, on this date.

12/06/00
Date

Rita H. Jennings
Rita H. Jennings

RECEIVED

DEC 18 2000

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
IN ACCORDANCE WITH 37 C.F.R. §§1.97-1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Because this Supplemental Information Disclosure Statement is filed after receipt of a First Office Action on the merits for the above-captioned application, the filing fee of \$240 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and cited reference are provided herewith in connection with the above-captioned application.

12/12/2000 HNDOR1 00000061 09127141

12/12/2000

100.00 02

Refund Ref:

12/12/2000 HNDOR1

0000100250

ME

U.S.S.N. 09/127,141
GRUENBERG
Supplemental IDS


The documents listed on the Forms PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing reference and it be made of record in the file history of the above-captioned application.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:


Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24731-500F
Address all correspondence to:
Stephanie L. Seidman, Esq.
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4250 Executive Square, Suite 700,
La Jolla, California 92037
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL sseidman@hewm.com